Not sure.
They seem to be implying tht the Australian sites may well have been inverted by stripping out the Australian results which are almost identical but opposite..
In the 2019 trial, the GSS benefit of Nasodine in the viralinfected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the
benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024).
They say there is no evidence they were switched.. 'at this time'.. does that mean that 'at another time' there might be eivdence? Who knows.
- Forums
- ASX - By Stock
- FRE
- Ann: Phase 3 Common Cold Trial Results
Ann: Phase 3 Common Cold Trial Results, page-10
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FRE (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
0.001(1.92%) |
Mkt cap ! $10.35M |
Open | High | Low | Value | Volume |
5.2¢ | 5.3¢ | 5.2¢ | $4.369K | 83.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 39391 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 0.051 |
2 | 78292 | 0.050 |
4 | 231128 | 0.049 |
1 | 100000 | 0.048 |
1 | 100000 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 39391 | 2 |
0.053 | 95055 | 1 |
0.055 | 12757 | 1 |
0.057 | 40821 | 1 |
0.060 | 1000 | 1 |
Last trade - 11.49am 03/07/2024 (20 minute delay) ? |
Featured News
FRE (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online